ADMA Q2 2022 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+90.2% YoY

Gross Profit

$8M22.9% margin

Operating Income

-$9M-27.1% margin

Net Income

-$14M-40.6% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+16.5%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$297M

Total Liabilities

$183M

Stockholders' Equity

$114M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$18M	+90.2%
Gross Profit	$8M	-$1M	+875.4%
Operating Income	-$9M	-$16M	+41.1%
Net Income	-$14M	-$19M	+27.2%

Revenue Segments

Product Revenue

$34M100%

License Revenue

$35,7090%

Geographic Segments

United States

$31M100%